Health · The Hindu · Health
Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
Source brief · The publisher’s headline and teaser, with a link to its report.
From The Hindu · Health
- The Paragraph IV certification sought is with respect to applicable patents listed in the U.S.
- FDA’s Orange Book.
- Granules said it has also issued the requisite notice to the relevant parties in accordance with U.S. regulatory requirements.
Behind this report
- News desk
- Health
- Published
- 2026-10-17T00:06:50.000Z
- Linked source records
- 2
Related source headlines
Read how the linked publishers describe the story. A list of reports is not independent verification.
- The Hindu · Health Zydus launches in U.S. MSN Labs generic of Bayer’s PAH drug
The available source material is a short summary. Check the linked reports for the full detail.
Places: United States
Sources and further reading
- The Hindu · Health — Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
- The Hindu · Health — Zydus launches in U.S. MSN Labs generic of Bayer’s PAH drug